Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRAS metastatic colorectal cancer: final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study).
Saved in:
| Title: | Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRAS metastatic colorectal cancer: final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study). |
|---|---|
| Authors: | Fernandez-Plana, Julen1 julenfernandez@mutuaterrassa.cat, Pericay, Carlos2 cpericay@gmail.com, Quintero, Guillermo3 gquinteroaldana@gmail.com, Alonso, Vicente4 valonsoo@salud.aragon.es, Salud, Antonieta5 asaluds@hotmail.com, Mendez, Miguel6 mmendez.hmtl@salud.madrid.org, Salgado, Mercedes7 mercedes.salgado.fernandez@sergas.es, Saigi, Eugeni2 esaigi@tauli.cat, Cirera, Luis8 lcirera@mutuaterrassa.es |
| Source: | BMC Cancer. 2014, Vol. 14 Issue 1, p1-17. 17p. 1 Diagram, 5 Charts. |
| Database: | Academic Search Ultimate |
| ISSN: | 14712407 |
|---|---|
| DOI: | 10.1186/1471-2407-14-865 |
